Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma D Høgdall, M Lewinska, JB Andersen Trends in cancer 4 (3), 239-255, 2018 | 113 | 2018 |
Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers D Høgdall, CJ O'Rourke, C Dehlendorff, OF Larsen, LH Jensen, ... Clinical cancer research 26 (21), 5655-5667, 2020 | 27 | 2020 |
Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma D Høgdall, CJ O'Rourke, A Taranta, DVNP Oliveira, JB Andersen Digestive Diseases 34 (4), 440-451, 2016 | 23 | 2016 |
Improved detection methods for infected hip joint prostheses D Høgdall, JJ Hvolris, L Christensen Apmis 118 (11), 815-823, 2010 | 21 | 2010 |
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma F Ole Larsen, D Taksony Solyom Hoegdall, E Hoegdall, D Nielsen Acta Oncologica 55 (3), 382-385, 2016 | 18 | 2016 |
MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells L Duwe, P Munoz-Garrido, M Lewinska, J Lafuente-Barquero, L Satriano, ... Journal of hepatology 78 (2), 364-375, 2023 | 11 | 2023 |
Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer D Høgdall, CJ O’Rourke, FO Larsen, S Zarforoushan, TD Christensen, ... Journal of hepatology 77 (4), 1047-1058, 2022 | 9 | 2022 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma FO Larsen, AH Mellergaard, DTS Hoegdall, LH Jensen Acta Oncologica 53 (10), 1448-1450, 2014 | 7 | 2014 |
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy CJ O'Rourke, M Salati, C Rae, G Carpino, H Leslie, A Pea, MG Prete, ... Gut 73 (3), 496-508, 2024 | 6 | 2024 |
Exome sequencing of 22 genes using tissue from patients with biliary tract cancer D Høgdall, OF Larsen, D Linnemann, T Svenstrup Poulsen, EV Høgdall Apmis 128 (1), 3-9, 2020 | 6 | 2020 |
Blood‐based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer TD Christensen, C Jensen, O Larsen, B Leerhøy, CP Hansen, K Madsen, ... International Journal of Cancer 152 (5), 1036-1049, 2023 | 5 | 2023 |
Protein signatures and individual circulating proteins, including IL-6 and IL-15, associated with prognosis in patients with biliary tract cancer TD Christensen, K Madsen, E Maag, O Larsen, LH Jensen, CP Hansen, ... Cancers 15 (4), 1062, 2023 | 5 | 2023 |
Genomic landscape of treatment refractory metastatic colorectal cancer RL Eefsen, KS Simonsen, P Grundtvig, L Klarskov, IM Chen, D Høgdall, ... Acta Oncologica 60 (12), 1621-1628, 2021 | 2 | 2021 |
Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities D Høgdall, CJ O'Rourke, JB Andersen Advances in cancer research 156, 343-366, 2022 | 1 | 2022 |
# 514 Potential targeted therapies for ovarian cancer beyond PARP inhibitors Y Sisman, D Høgdall, TS Henrichsen, C Høgdall, E Høgdall International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy JOR Colm, M Salati, C Rae, G Carpino, H Leslie, A Pea, GP Maria, ... EGUT, 2023 | | 2023 |
Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer. Cancers 2023, 15, 1062 TD Christensen, K Madsen, E Maag, O Larsen, LH Jensen, CP Hansen, ... | | 2023 |
MicroRNA-27a-3p modulates FoxO1 to induce tumor-like phenotypes in CCA P Munoz-Garrido, L Duwe, L Satriano, M Lewinska, J Lafuente-Barquero, ... JOURNAL OF HEPATOLOGY 75, S240-S240, 2021 | | 2021 |
Characterization of miR deregulation in cholangiocarcinoma (CCA): Consequences in tumor heterogeneity and drug resistance P Munoz-Garrido, L Satriano, D Høgdall, J Banales, A Ghazal, CO Rourke, ... Journal of Hepatology 68, S74, 2018 | | 2018 |
Prognostic impact of plasma CA 19-9, IL-6 and YKL-40 in patients with inoperable cholangiocarcinoma. D Hogdall, C Dehlendorff, MK Boisen, O Larsen, JS Johansen Journal of Clinical Oncology 34 (15_suppl), e15638-e15638, 2016 | | 2016 |